Ainos To Initiate Clinical Study Of New VELDONA-Based Animal Drug, Expanding Potential Market
Ainos To Initiate Clinical Study Of New VELDONA-Based Animal Drug, Expanding Potential Market
Ainos將啓動基於Veldona的新動物藥物的臨床研究，擴大潛在市場
- Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the initiation of a clinical study for a new potential VELDONA-based drug for pet disease. The study is aimed at evaluating the clinical efficacy of low-dose oral interferons in treating feline chronic gingivostomatitis ("FCGS"), a serious and chronic painful oral disease characterized by inflammation or abnormal proliferation in the oral cavity.
- Ainos, Inc.（納斯達克股票代碼：AIMD，AIMDW）））（“Ainos” 或 “公司”）是一家專注於開發新型即時檢測、低劑量干擾素療法和合成RNA驅動的預防藥物的多元化醫療保健公司，今天宣佈啓動一項針對寵物疾病的潛在基於Veldona的新藥物的臨床研究。該研究旨在評估低劑量口服干擾素治療貓慢性牙齦炎（“FCGS”）的臨床療效，貓慢性牙齦炎是一種以口腔炎症或異常增殖爲特徵的嚴重慢性口腔疼痛性疾病。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。